

Comments from Mattias Perjos, CEO

High organic sales growth and stronger margins despite geopolitical headwinds

We demonstrated strength in the third quarter with significant organic growth, improved profitability and cash flow – despite stronger headwinds from tariffs and negative currency effects. Acute Care Therapies continued to meet the higher demand for ventilators, in the wake of the ongoing market consolidation. Order intake and sales of ECLS consumables were also significant. Both Life Science and Surgical Workflows set sales records for the third quarter, mainly due to persistently robust growth in Sterile Transfer and the strong demand for operating tables in Surgical Workplaces.

One year has now passed since Paragonix became part of Getinge and the company is included organically from September. It is encouraging to see the organization's success at conducting business and we now look forward to increasing the pace of expansion initiated in selected markets outside the US.

During the quarter, we got the CE Mark back for our intra-aortic balloon pump Cardiosave and deliveries are expected to resume in the fourth quarter. Recently, also our V12 balloon expandable covered stent received approval for three further indications, which is key to strengthening our position in the European market.

Adjusted EBITA increased in the quarter, despite tariff costs and currency effects totaling SEK -236 M compared with last year. Our price adjustment strategy remains successful, but short term we need to absorb a large share of the tariff costs. However, intensified efforts to improve cost efficiency and boost productivity are generating results and in general, we are successfully keeping material cost development under control. In some product categories in Life Science, we have been able to reduce lead time and cost of goods sold significantly.

We are now entering a fourth quarter with tough comparative figures, but we are essentially well positioned to manage these geopolitical challenges by leveraging our leading position in key niches that meet long-term increasing healthcare needs on a global level. Considering the tariff levels to date, we have therefore chosen to reiterate our financial target.

Finally, I would like to thank all our customers and employees for their important efforts in creating value for clinical staff and patients.

July – September 2025 in brief

- Net sales increased organically by 9.5% (0.2) and the order intake rose by 4.7% organically (7.4).
- Adjusted gross profit amounted to SEK 4,051 M (3,799) and the margin was 49.2% (48.3).
- Adjusted EBITA amounted to SEK 1,079 M (903) and the margin was 13.1% (11.5).
- Adjusted earnings per share amounted to SEK 2.42 (2.24).
- Free cash flow amounted to SEK 793 M (357).

January – September 2025 in brief

- Net sales increased organically by 6.6% (3.0) and the order intake rose by 4.0% organically (5.9).
- Adjusted gross profit amounted to SEK 12,570 M (11,805) and the margin was 50.7% (49.8).
- Adjusted EBITA amounted to SEK 3,071 M (2,726) and the margin was 12.4% (11.5).
- Adjusted earnings per share amounted to SEK 6.84 (6.45).
- Free cash flow amounted to SEK 1,462 M (1,590).

Outlook 2025: Net sales for 2025 are expected to increase by 2–5% organically. *(unchanged)*

Summary of financial performance¹⁾

SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Order intake	8,477	8,486	25,470	24,959	34,232
Organic change, %	4.7	7.4	4.0	5.9	6.3
Net sales	8,226	7,870	24,783	23,688	34,759
Organic change, %	9.5	0.2	6.6	3.0	4.9
Adjusted gross profit	4,051	3,799	12,570	11,805	17,409
Margin, %	49.2	48.3	50.7	49.8	50.1
Adjusted EBITDA	1,501	1,343	4,353	4,014	6,646
Margin, %	18.2	17.1	17.6	16.9	19.1
Adjusted EBITA	1,079	903	3,071	2,726	4,869
Margin, %	13.1	11.5	12.4	11.5	14.0
Adjusted EBIT	986	821	2,776	2,528	4,549
Margin, %	12.0	10.4	11.2	10.7	13.1
Operating profit (EBIT)	952	184	2,418	1,769	2,854
Margin, %	11.6	2.3	9.8	7.5	8.2
Profit before tax	789	32	1,938	1,371	2,282
Net profit for the period	576	8	1,407	986	1,654
Adjusted net profit for the period	668	618	1,880	1,768	3,211
Margin, %	8.1	7.9	7.6	7.5	9.2
Adjusted earnings per share, SEK	2.42	2.24	6.84	6.45	11.73
Earnings per share, SEK	2.08	0.01	5.10	3.58	6.01
Cash flow from operating activities	1,084	680	2,395	2,538	4,577
Free cash flow	793	357	1,462	1,590	3,284

1) See page 3 for calculations of adjusted performance measures.

Group performance

Order intake

Order intake business areas, SEK M	Jul-Sep 2025	Jul-Sep 2024	Org Δ, %	Jan-Sep 2025	Jan-Sep 2024	Org Δ, %	Jan-Dec 2024
Acute Care Therapies	4,375	4,238	6.5	13,682	12,797	6.6	17,719
Life Science	1,232	1,064	21.9	3,264	3,388	0.2	4,601
Surgical Workflows	2,869	3,183	-3.6	8,524	8,773	1.7	11,912
Total	8,477	8,486	4.7	25,470	24,959	4.0	34,232

Order intake regions, SEK M	Jul-Sep 2025	Jul-Sep 2024	Org Δ, %	Jan-Sep 2025	Jan-Sep 2024	Org Δ, %	Jan-Dec 2024
Americas	3,781	3,807	2.8	11,634	11,071	4.5	15,188
APAC	1,615	1,835	-3.8	4,782	5,150	-1.8	7,031
EMEA	3,080	2,844	12.5	9,053	8,737	6.7	12,013
Total	8,477	8,486	4.7	25,470	24,959	4.0	34,232

Net sales


Net sales business areas, SEK M	Jul-Sep 2025	Jul-Sep 2024	Org Δ, %	Jan-Sep 2025	Jan-Sep 2024	Org Δ, %	Jan-Dec 2024
Acute Care Therapies	4,339	4,022	11.4	13,594	12,423	9.1	17,948
Life Science	1,097	1,003	15.9	3,171	3,060	7.8	4,552
Surgical Workflows	2,789	2,845	4.7	8,018	8,205	2.3	12,258
Total	8,226	7,870	9.5	24,783	23,688	6.6	34,759

Net sales regions, SEK M	Jul-Sep 2025	Jul-Sep 2024	Org Δ, %	Jan-Sep 2025	Jan-Sep 2024	Org Δ, %	Jan-Dec 2024
Americas	3,723	3,677	4.7	11,617	11,003	5.0	15,516
APAC	1,655	1,560	15.9	4,849	4,611	11.3	7,061
EMEA	2,848	2,633	12.4	8,317	8,074	6.0	12,182
Total	8,226	7,870	9.5	24,783	23,688	6.6	34,759

Net sales specified by capital goods and recurring revenue, SEK M	Jul-Sep 2025	Jul-Sep 2024	Org Δ, %	Jan-Sep 2025	Jan-Sep 2024	Org Δ, %	Jan-Dec 2024
Capital goods	2,675	2,591	10.5	7,785	7,734	5.6	12,421
Recurring revenue ¹⁾	5,551	5,279	9.1	16,999	15,954	7.0	22,338
Total	8,226	7,870	9.5	24,783	23,688	6.6	34,759

1) Consumables, service and spare parts

Net sales – bridge between Q3 2024 and Q3 2025



- The organic order intake for Acute Care Therapies increased mainly due to ventilators in Critical Care and ECLS consumables.
- Life Science reported double-digit growth in the organic order intake for the quarter due to the very strong performance in Sterile Transfer.
- The organic order intake for Surgical Workflows declined in the quarter despite a strong trend for operating tables and consumables in Infection Control.
- Geographically, the organic order intake trend was positive in both EMEA and Americas. It declined slightly in APAC, mainly due to higher order intake last year in Australia.

- Acute Care Therapies increased its net sales organically, mainly due to the continued very strong performance in ventilators, ECLS therapy and Cardiac Surgery.
- Organic net sales for Life Science reported a double-digit increase due to healthy growth in Sterile Transfer and WIS.
- In Surgical Workflows, organic net sales rose due to growth in Infection Control and operating tables in Surgical Workplaces.
- Positive organic growth in all regions, with particularly high growth in APAC and EMEA following the strong performance in for example China and Germany.
- Recurring revenues increased in the quarter, with sales contributions from consumables in ECLS Therapy, Cardiac Surgery, Sterile Transfer and Vascular Interventions among others. Sales of capital goods also increased in the quarter, mainly attributable to ventilators and operating tables.

- Net sales increased by SEK 356 M, corresponding to +4.5%.
- Net sales from acquisitions had an impact of SEK +203 M, corresponding to +2.6%.
- Exchange rates had an impact of SEK -596 M on sales, corresponding to -7.6%.
- Successful efforts with price adjustments and volumes had an impact of SEK +749 M on sales, corresponding to +9.5%.

Earnings trend

- Currency effects impacted adjusted gross profit by SEK -332 M and adjusted EBITA by SEK -128 M compared with last year.
- The gross margin increased due to acquisitions, price adjustments and a favorable product mix.
- Adjusted EBITA rose by SEK 176 M, despite tariff effects of approximately SEK -108 M and negative currency effects compared with last year. The margin improved by 1.6 percentage points.
- Acquisition and restructuring costs are mainly related to the ongoing rationalizations in the organization.
- Net financial items amounted to SEK -163 M, mainly as a result of higher net debt year-on-year.
- The year-to-date tax rate was 27.4%.

SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Net sales	8,226	7,870	24,783	23,688	34,759
Adjusted gross profit	4,051	3,799	12,570	11,805	17,409
Margin, %	49.2	48.3	50.7	49.8	50.1
Adjusted operating expenses	-2,550	-2,456	-8,217	-7,792	-10,764
Adjusted EBITDA	1,501	1,343	4,353	4,014	6,646
Margin, %	18.2	17.1	17.6	16.9	19.1
Depreciation, amortization and write-downs of intangible assets and tangible assets ¹⁾	-422	-440	-1,282	-1,288	-1,776
Adjusted EBITA	1,079	903	3,071	2,726	4,869
Margin, %	13.1	11.5	12.4	11.5	14.0
A Amortization and write-down of acquired intangible assets ¹⁾	-93	-82	-294	-198	-320
Adjusted EBIT	986	821	2,776	2,528	4,549
Margin, %	12.0	10.4	11.2	10.7	13.1
B Acquisition and restructuring costs	-33	-155	-359	-276	-898
C Other items affecting comparability ²⁾	-	-482	-	-482	-797
Operating profit (EBIT)	952	184	2,418	1,769	2,854
Net financial items	-163	-152	-480	-398	-571
Profit before tax	789	32	1,938	1,371	2,282
Adjusted profit before tax (adjusted for A, B and C)	916	751	2,591	2,328	4,298
Margin, %	11.1	9.5	10.5	9.8	12.4
Taxes	-214	-24	-531	-385	-628
D Tax on adjustment items ²⁾	-35	-109	-180	-175	-459
Adjusted net profit for the period (adjusted for A, B, C and D)	668	618	1,880	1,768	3,211
Margin, %	8.1	7.9	7.6	7.5	9.2
Of which, attributable to Parent Company shareholders	658	611	1,863	1,756	3,195
Average number of shares, thousands	272,370	272,370	272,370	272,370	272,370
Adjusted earnings per share, SEK (adjusted for A, B, C and D)	2.42	2.24	6.84	6.45	11.73

1) Excluding items affecting comparability (see Note 4 Depreciation, amortization and write-downs).

2) See Note 6 Adjustment items


Adjusted EBITA per business area¹⁾

- Adjusted EBITA for Acute Care Therapies rose by SEK 126 M and the margin increased by 1.8 percentage points.
- Life Science's adjusted EBITA increased by SEK 40 M and the margin by 2.8 percentage points.
- Adjusted EBITA for Surgical Workflows rose by SEK 12 M and the margin by 0.6 percentage points.
- Costs in Group functions and other were largely unchanged year-on-year.

SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Acute Care Therapies	763	637	2,624	2,247	3,554
Margin, %	17.6	15.8	19.3	18.1	19.8
Life Science	141	101	318	315	608
Margin, %	12.9	10.1	10.0	10.3	13.4
Surgical Workflows	263	251	453	420	1,090
Margin, %	9.4	8.8	5.6	5.1	8.9
Group functions and other (incl. eliminations)	-89	-86	-323	-256	-383
Total	1,079	903	3,071	2,726	4,869
Margin, %	13.1	11.5	12.4	11.5	14.0

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability.

Adjusted EBITA – bridge between Q3 2024 and Q3 2025



- Adjusted operating expenses for selling and administration increased organically by 4.0%, mainly due to higher sales activities. Inorganically, these expenses increased by 2.2%.
- The year-on-year difference for other operating income and expenses was mainly attributable to currency effects related to operating receivables and liabilities in foreign currency.

- Exchange-rate fluctuations, meaning translation and transaction effects, impacted adjusted gross profit by SEK -332 M compared with last year, of which SEK -233 M in translation effects and SEK -99 M in transaction effects and hedging outcome.
- The change in adjusted EBITA attributable to currency effects was SEK -128 M, of which SEK -66 M arose from translation effects and SEK -62 M from the net of transaction effects, hedging outcome, and revaluation of operating receivables and liabilities in foreign currency.

- Compared with last year, free cash flow was positively impacted by higher operating profit. Working capital increased, but to a lesser extent compared with the third quarter last year, due to, for example, lower inventories.
- The financial position remains solid, although net interest-bearing debt has increased after the acquisition of Paragonix Technologies, Inc.

- Costs for R&D were 5.4% lower year-on-year.
- Capitalized development costs were 6.4% lower compared with last year.
- The year-on-year difference was mainly due to lower costs for quality-related improvements.
- Depreciation and write-downs amounted to SEK -98 M (-102), of which write-downs SEK -4 M (0).

Adjusted operating expenses

(excluding depreciation, amortization and write-downs and other items affecting comparability)¹⁾

SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Selling expenses	-1,256	-1,242	-3,978	-3,941	-5,355
Administrative expenses	-990	-955	-3,100	-3,005	-4,240
Research and development costs	-286	-302	-913	-935	-1,332
Other operating income and expenses	-17	44	-226	90	164
Total	-2,550	-2,456	-8,217	-7,792	-10,764

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability.

Currency impact

SEK M	Jul-Sep 2025	Jan-Sep 2025
Net sales	-596	-1,193
Adjusted gross profit	-332	-633
Adjusted EBITDA	-148	-412
Adjusted EBITA	-128	-369
Adjusted EBIT	-124	-363

Cash flow and financial position¹⁾

SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Cash flow before changes in working capital	1,141	801	3,327	2,931	5,036
Changes in working capital ²⁾	-56	-120	-932	-393	-459
Net investments in non-current assets	-292	-323	-933	-948	-1,294
Free cash flow	793	357	1,462	1,590	3,284
Net interest-bearing cash/debt			11,061	11,284	10,467
<i>In relation to adjusted EBITDA¹⁾ R12M, multiple</i>			1.6	2.0	1.6
Net interest-bearing cash/debt, excl. pension provisions			8,582	8,627	7,766
<i>In relation to adjusted EBITDA¹⁾ R12M, multiple</i>			1.2	1.5	1.2

1) See Note 6 Adjustment items for items affecting comparability and Note 8 for alternative performance measures.

2) Non-cash financial items were reclassified to operating liabilities for the 2024 comparative figures.

Research and development

SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Research and development costs	-434	-459	-1,407	-1,434	-1,992
Amortization, depreciation and write-downs	-21	-17	-55	-50	-99
Research and development costs, gross	-454	-476	-1,462	-1,484	-2,091
<i>In relation to net sales, %</i>	5.5	6.0	5.9	6.3	6.0
Capitalized development costs	147	157	494	499	660
<i>In relation to net sales, %</i>	1.8	2.0	2.0	2.1	1.9
Research and development costs, net	-307	-319	-968	-985	-1,431
Amortization and write-down of capitalized development costs¹⁾	-98	-102	-297	-293	-707

1) Capitalized development projects

- CO2 emission has decreased, mainly due to a higher share of renewable electricity and gas.
- Water consumption is mainly related to facilities management and testing in production of washers and sterilizers and varies over time depending on production volume. The outcome showed a rising trend due to higher degree of testing in production and increase in water for facilities at one of our sites.
- The employee engagement index was updated with the results of the survey in Q2 2025. The score was 73, up 2 points compared with the previous survey, reflecting a positive trend in engagement. This resulted in an outcome of 72 on a rolling 12 months basis.
- It was discovered in the reporting process that data for WRAR had been incorrectly reported. The error affected the number of hours worked and has been corrected. Action has been taken to reduce the risk of errors occurring in the future. The previously reported figure for WRAR for the full-year 2024 was 0.92 and this has now been corrected to 0.99.
- The regulatory compliance KPI improved compared with the full-year 2024 since the first quarters of 2024 included a higher number of audit findings per audit.
- The KPI for product quality was based on the number of new field actions.
- The positive trend for online customer training was maintained.
- A positive trend over time for the business ethics KPI.
- As noted in the 2024 Sustainability Report, the genders of the employees in Paragonix were not correctly registered. This has been updated from the Q2 report.
- KPIs for Q1 2025 and beyond have been adjusted. Water consumption has been added. Sick leave has been replaced with work-related accidents in relation to working hours (Work Related Accident Rate, WRAR) The KPIs for waste and for workers in the value chain are presented every year in the Sustainability Report but are not reported every quarter.
- CO2 and energy data for the companies Ultra Clean, Healthmark and Paragonix is not included in the ongoing quarterly reporting since these companies were acquired less than 24 months ago. Full-year figures for these companies, and for Quadralene, will be reported in the 2025 Sustainability Report.

Sustainability developments

This interim report reflects Getinge's double materiality assessment and is based on the ESRS structure to present the company's impact, risks and opportunities from a social, environmental and governance perspective. The aim is to continuously work to minimize the negative impact on people and the environment and to generate sustainable value for customers, employees and other stakeholders.

Key areas	R12 Sep 2025 ¹⁾	R12 Sep 2024 ¹⁾	Δ, % ²⁾	Jan-Dec 2024	Δ, % ³⁾
Environment, Climate & Energy					
Scope 1 & 2 GHG emissions in production, ton CO ₂ equivalents ⁷⁾	3,656	4,841	-24.5	4,163	-12.2
Total energy consumption in production, MWh ⁷⁾	76,439	78,805	-3.0	77,117	-0.9
Percentage of renewable energy of total energy, % ⁷⁾	74	66	8.0*	70	4.0*
Water consumption in sites located in water scarce areas, m ³ ⁴⁾	100,737	87,802	14.7	93,115	8.2
Social					
Own workforce					
Employee engagement, % ⁵⁾	72	71	1.0*	71	1.0*
Percentage of female employees, % ⁶⁾	37.9	37.2	0.7*	37.7	0.2*
Percentage of female managers, % ⁶⁾	34.3	33.9	0.4*	34.5	-0.2*
Work Related Accident Rate, WRAR	0.85	0.88	-3.0	0.99	-13.8
Consumers and end-users					
Regulatory compliance, audit findings per audit for quality systems ^{7,8)}	1.6	2.2	-27.9	2.5	-37.8
Product quality, field actions per SEK billion in net revenue ⁷⁾	1.1	1.4	-23.9	1.2	-10.0
Online customer training ⁷⁾	50,862	46,047	10.5	48,486	4.9
Governance					
Business ethics					
Percentage of employees who completed training in business ethics, %	92	90	2.0*	90	2.0*

*) Change in percentage points

1) R12 = Rolling 12 months

2) Index R12 Sep 2025/R12 Sep 2024

3) Index R12 Sep 2025/Jan-Dec 2024

4) Eight manufacturing sites were in the scope of the 2024 Sustainability Report. A more detailed investigation has revealed that one of these sites was outside the area of water stress defined as "high" and "extremely high" by the WRI Water Risk Atlas tool Aqueduct. Accordingly, this site is no longer included in the reporting. The annual and quarterly figures have been adjusted and will also be updated retroactively in the 2025 Sustainability Report.

5) Measured and updated every six months

6) Amount at end of period

7) Data was recalculated in 2024. See Getinge's 2024 Sustainability Report for more details

8) Getinge has updated the reporting of its results to better reflect the timing of audit reports, which means that data is reported with a delay of one quarter.

Acute Care Therapies

Acute Care Therapies offers world-leading solutions for life support in acute health conditions. The offering includes solutions for cardiovascular procedures, efficient handling of organs for transplantation and a broad selection of products and therapies for intensive care.

- The organic order intake for Acute Care Therapies increased, mainly due to ventilators in Critical Care and ECLS consumables.
- Geographically, the organic order intake increased in all regions following growth in almost all countries.

- Acute Care Therapies increased its net sales organically, mainly due to the continued very strong performance in ventilators, ECLS therapy and Cardiac Surgery.
- Sales increased organically in all regions, with a particularly favorable performance continuing in EMEA.
- Recurring revenue noted a strong organic performance, with contributions from both consumables and service. Capital goods also increased organically.

- The adjusted gross margin improved by 1.8 percentage points, largely due to higher volumes, price and favorable product mix.
- Adjusted selling and administrative expenses increased organically by 6.2%, mainly as a result of higher sales activities. Inorganically, these expenses rose by 7.9%.
- Adjusted EBITA increased by SEK 126 M due to volumes and a favorable product mix despite tariffs and negative currency effects. The margin increased by 1.8 percentage points.
- Currency effects impacted sales by SEK -343 M, adjusted gross profit by SEK -215 M and adjusted EBITA by SEK -97 M compared with last year.

Order intake and net sales

Order intake regions, SEK M	Jul-Sep 2025	Jul-Sep 2024	Org Δ, %	Jan-Sep 2025	Jan-Sep 2024	Org Δ, %	Jan-Dec 2024
Americas	2,261	2,125	6.5	7,380	6,480	9.1	9,120
APAC	964	972	8.1	2,785	2,805	5.0	3,897
EMEA	1,150	1,141	5.1	3,516	3,512	3.1	4,702
Total	4,375	4,238	6.5	13,682	12,797	6.6	17,719

Net sales regions, SEK M	Jul-Sep 2025	Jul-Sep 2024	Org Δ, %	Jan-Sep 2025	Jan-Sep 2024	Org Δ, %	Jan-Dec 2024
Americas	2,289	2,103	8.9	7,357	6,470	8.9	9,223
APAC	922	915	10.6	2,837	2,748	9.3	3,983
EMEA	1,128	1,004	17.2	3,400	3,205	9.2	4,742
Total	4,339	4,022	11.4	13,594	12,423	9.1	17,948

Net sales specified by capital goods and recurring revenue, SEK M	Jul-Sep 2025	Jul-Sep 2024	Org Δ, %	Jan-Sep 2025	Jan-Sep 2024	Org Δ, %	Jan-Dec 2024
Capital goods	890	870	11.8	2,873	2,719	11.9	4,318
Recurring revenue ¹⁾	3,449	3,152	11.2	10,722	9,704	8.3	13,631
Total	4,339	4,022	11.4	13,594	12,423	9.1	17,948

1) Consumables, service and spare parts

Earnings trend¹⁾

SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Net sales	4,339	4,022	13,594	12,423	17,948
Adjusted gross profit	2,456	2,205	7,951	7,193	10,417
Margin, %	56.6	54.8	58.5	57.9	58.0
Adjusted EBITDA	972	867	3,271	2,922	4,474
Margin, %	22.4	21.6	24.1	23.5	24.9
Depreciation, amortization and write-downs of intangible assets and tangible assets	-209	-231	-647	-675	-920
Adjusted EBITA	763	637	2,624	2,247	3,554
Margin, %	17.6	15.8	19.3	18.1	19.8

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability.

Events in the business area in the quarter

- Getinge received the CE Mark back for Cardiosave Intra-Aortic Balloon Pump. The reinstatement is subject to certain conditions, which Getinge is committed to fulfilling.
- Getinge and Philips have joined forces to offer hospitals in CE markets an integrated anesthesia workstation for the operating room (OR). The new solution unites precise anesthesia delivery and state-of-the-art patient monitoring.
- Further progress was made in EU MDR certification. The most recent milestone was approval of further indications for our V12 balloon expandable covered stents. The approval of three different indicators (BEVAR, FEVAR and IBD) represents a key enabler for growth in the European endovascular market.

Life Science

Life Science offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in pharmaceutical and medical device production and with the aim to strengthen integrity of results in biomedical research.

- Life Science reported double-digit growth in the organic order intake for the quarter due to the very strong performance in Sterile Transfer.
- The trend in Bio-Processing remained weak, with a particularly challenging situation in Americas.
- Both EMEA and APAC reported double-digit growth for their organic order intake following a positive trend in most product categories.

- Organic net sales for Life Science reported a double-digit increase due to healthy growth in Sterile Transfer and WIS.
- Organic sales increased substantially in APAC and EMEA, but declined in Americas due to Bio-Processing.
- Capital goods increased in all product categories in the quarter. The trend in recurring revenue was also favorable, driven by strong growth in Sterile Transfer and a continued positive performance in Service.

- The adjusted gross margin declined by 2.0 percentage points, mainly due to tariffs and currencies.
- Adjusted selling and administrative expenses declined organically by 3.6% due to a continued focus on productivity. Inorganically, these expenses fell by 8.8%.
- Adjusted EBITA rose by SEK 40 M and the margin increased by 2.8 percentage points.
- Currency effects impacted sales by SEK -65 M, adjusted gross profit by SEK -31 M and adjusted EBITA by SEK -9 M compared with last year.

Order intake and net sales

Order intake regions, SEK M	Jul-Sep 2025	Jul-Sep 2024	Org Δ, %	Jan-Sep 2025	Jan-Sep 2024	Org Δ, %	Jan-Dec 2024
Americas	414	534	-16.3	1,124	1,455	-18.6	1,862
APAC	145	120	30.7	399	415	1.5	573
EMEA	673	410	69.2	1,742	1,518	17.8	2,166
Total	1,232	1,064	21.9	3,264	3,388	0.2	4,601

Net sales regions, SEK M	Jul-Sep 2025	Jul-Sep 2024	Org Δ, %	Jan-Sep 2025	Jan-Sep 2024	Org Δ, %	Jan-Dec 2024
Americas	391	443	-4.0	1,179	1,349	-7.8	1,937
APAC	192	142	45.0	438	340	35.7	559
EMEA	514	418	27.0	1,553	1,371	16.3	2,057
Total	1,097	1,003	15.9	3,171	3,060	7.8	4,552

Net sales specified by capital goods and recurring revenue, SEK M	Jul-Sep 2025	Jul-Sep 2024	Org Δ, %	Jan-Sep 2025	Jan-Sep 2024	Org Δ, %	Jan-Dec 2024
Capital goods	460	376	29.2	1,274	1,191	11.1	1,970
Recurring revenue ¹⁾	638	627	7.8	1,897	1,868	5.7	2,582
Total	1,097	1,003	15.9	3,171	3,060	7.8	4,552

1) Consumables, service and spare parts

Earnings trend¹⁾

SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Net sales	1,097	1,003	3,171	3,060	4,552
Adjusted gross profit	401	386	1,208	1,191	1,808
<i>Margin, %</i>	<i>36.5</i>	<i>38.5</i>	<i>38.1</i>	<i>38.9</i>	<i>39.7</i>
Adjusted EBITDA	197	154	484	471	818
<i>Margin, %</i>	<i>18.0</i>	<i>15.3</i>	<i>15.3</i>	<i>15.4</i>	<i>18.0</i>
Depreciation, amortization and write-downs of intangible assets and tangible assets	-56	-53	-167	-156	-211
Adjusted EBITA	141	101	318	315	608
<i>Margin, %</i>	<i>12.9</i>	<i>10.1</i>	<i>10.0</i>	<i>10.3</i>	<i>13.4</i>

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability.

Events in the business area in the quarter

- A steadfast focus on productivity resulted in further efficiency improvements. For example, the lead time for GSS/GEV sterilizers has been reduced by more than 20% and COGS for certain capital goods in WIS by about 10%.

Surgical Workflows

Surgical Workflows offers products and solutions to serve as an end-to-end partner for optimizing the quality, safety and capacity usage of the sterile supply departments and operating rooms.

- The organic order intake for Surgical Workflows declined in the quarter, despite a strong trend for operating tables and consumables in Infection Control. The decline was primarily attributed to capital goods in Infection Control.
- Growth remained high in North America. APAC had challenging comparative figures for Australia and Japan. The development was however positive in China.

- In Surgical Workflows, organic net sales rose due to growth in Infection Control and operating tables in Surgical Workplaces.
- Geographically, APAC reported strong growth in all product categories. EMEA also performed well, while sales in the Americas were largely unchanged.
- There was solid growth in both recurring revenue and capital goods in the quarter.

- The adjusted gross margin increased by 0.3 percentage points, primarily as a result of price and volumes, while tariffs and inflation negatively impacted the margin.
- Adjusted selling and administrative expenses increased organically by 2.3%, as a result of higher sales activities. Inorganically, these expenses fell by 3.8%.
- Adjusted EBITA rose by SEK 12 M and the margin strengthened by 0.6 percentage points, mainly due to higher gross profit.
- Currency effects impacted sales by SEK -188 M, adjusted gross profit by SEK -85 M and adjusted EBITA by SEK -24 M compared with last year.

Order intake and net sales

Order intake regions, SEK M	Jul-Sep 2025	Jul-Sep 2024	Org Δ, %	Jan-Sep 2025	Jan-Sep 2024	Org Δ, %	Jan-Dec 2024
Americas	1,106	1,148	4.9	3,130	3,135	5.7	4,206
APAC	506	742	-25.0	1,598	1,931	-12.4	2,561
EMEA	1,257	1,293	1.2	3,796	3,707	5.6	5,145
Total	2,869	3,183	-3.6	8,524	8,773	1.7	11,912

Net sales regions, SEK M	Jul-Sep 2025	Jul-Sep 2024	Org Δ, %	Jan-Sep 2025	Jan-Sep 2024	Org Δ, %	Jan-Dec 2024
Americas	1,043	1,131	0.3	3,081	3,183	2.4	4,356
APAC	540	503	17.5	1,575	1,523	9.5	2,519
EMEA	1,206	1,211	3.4	3,363	3,499	-0.9	5,383
Total	2,789	2,845	4.7	8,018	8,205	2.3	12,258

Net sales specified by capital goods and recurring revenue, SEK M	Jul-Sep 2025	Jul-Sep 2024	Org Δ, %	Jan-Sep 2025	Jan-Sep 2024	Org Δ, %	Jan-Dec 2024
Capital goods	1,325	1,345	4.3	3,638	3,824	-0.6	6,133
Recurring revenue ¹⁾	1,465	1,500	5.0	4,380	4,382	4.8	6,125
Total	2,789	2,845	4.7	8,018	8,205	2.3	12,258

1) Consumables, service and spare parts

Earnings trend¹⁾

SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Net sales	2,789	2,845	8,018	8,205	12,258
Adjusted gross profit	1,194	1,208	3,410	3,422	5,185
<i>Margin, %</i>	<i>42.8</i>	<i>42.5</i>	<i>42.5</i>	<i>41.7</i>	<i>42.3</i>
Adjusted EBITDA	419	406	915	870	1,728
<i>Margin, %</i>	<i>15.0</i>	<i>14.3</i>	<i>11.4</i>	<i>10.6</i>	<i>14.1</i>
Depreciation, amortization and write-downs of intangible assets and tangible assets	-155	-155	-463	-450	-638
Adjusted EBITA	263	251	453	420	1,090
<i>Margin, %</i>	<i>9.4</i>	<i>8.8</i>	<i>5.6</i>	<i>5.1</i>	<i>8.9</i>

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability.

Events in the business area in the quarter

- Sweden's first fully automated Central Sterile Supply Department (CSSD) at Malmö University Hospital has been inaugurated, with Getinge's T-DOC providing the software intelligence that optimizes sterile supply management. By enhancing quality, patient safety, cost efficiency and the human work environment, T-DOC is a critical enabler of successful CSSD optimization. The facility is set to be fully operational in early 2026. Since pioneering the world's first automated CSSD in 2011, T-DOC has been implemented in several sterile supply automation projects across Europe and Asia, strengthening its role as a leader in CSSD optimization.

Other information

Events after the end of the reporting period

There are no significant events to report.

Seasonal variations

Getinge's sales and earnings are affected by seasonal variations. The highest net sales are usually generated in the fourth quarter, followed by the second, third and first quarters. The shares of sales derived from capital goods and recurring revenue also normally changes during the year, with a higher share of sales of capital goods toward the end of the year.

Transactions with related parties

Getinge carried out normal commercial transactions with companies in the Carl Bennet AB sphere, which comprised the sale and purchase of goods and services. In addition, no other significant transactions with related parties occurred during the period other than transactions with subsidiaries.

Forward-looking information

This report contains forward-looking information based on the current expectations of company management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding finances, market and competition, changes in legal and regulatory requirements and other political measures, and fluctuations in exchange rates.

Getinge's financial targets 2024–2028 and dividend policy

- Average adjusted earnings per share growth: >12%*
- Getinge's dividend policy is to pay dividends of 30-50% of net profit to shareholders.

Getinge's sustainability targets

Environment

- Reduce Scope 1 and 2 emissions by 90% by 2030**
- Reduce Scope 3 emissions by 25% by 2030, and by 90% by 2050**
- Reduce energy consumption in production by 20% by 2030**
- Reduce water consumption in sites located in water scarce areas by 20% by 2030**
- No waste to landfill by 2030, excluding material required by local regulations to be landfilled

Social

- Employee engagement: >70%
- Reduce work-related accidents in relation to working hours (Work Related Accident Rate, WRAR) to less than 1 by 2025
- Ensure equal employment opportunity and non-discrimination across all levels of the organization Follow-up % female vs male managers and employees
- Quality regulatory compliance, audit results/inspection: <1.5 deviation

Governance

- All employees are properly trained in Business ethics

**Base year 2023*

*** Base year 2021*

Nomination Committee ahead of 2026 Annual General Meeting

Ahead of the Annual General Meeting, the Nomination Committee shall, in accordance with the principles adopted at the 2020 Annual General Meeting, be composed of members appointed by the four largest shareholders in terms of voting rights, based on a list of owner-registered shareholders from Euroclear Sweden AB or other reliable ownership information, as of August 31 of each year, and the Chairman of the Board of Directors. In addition, if the Chairman of the Board in consultation with the member appointed by the largest shareholder in terms of voting rights deems it appropriate, it shall include an, in relation to the company and its major shareholders, independent representative of the minority shareholders as a member of the Nomination Committee.

Getinge's Nomination Committee ahead of the 2026 Annual General Meeting has been appointed and comprises the company's Chairman Johan Malmquist, and representatives from the following owners, listed by size.

- **Carl Bennet AB:** Carl Bennet, Chairman of the Nomination Committee
- **Fourth Swedish National Pension Fund:** Jannis Kitsakis
- **AMF Pension & Fonder:** Sophie Larsén
- **Carnegie fonder:** Anna Strömberg

Shareholders who wish to submit proposals to Getinge's 2026 Nomination Committee can contact the Nomination Committee by e-mail at valberedningen@getinge.com or by mail to the following address: Getinge AB, Att: Nomination Committee, Box 8861, SE-402 72 Gothenburg, Sweden. Proposals must be received by the Nomination Committee no later than January 16, 2026 in order to ensure that they are addressed by the Committee.

2026 Annual General Meeting

Getinge AB's Annual General Meeting will be held on April 21, 2026 in Halmstad, Sweden.

Shareholders who wish to have a matter addressed at the Annual General Meeting may submit their proposal to Getinge's Board Chairman via e-mail: arenden.bolagsstamma@getinge.com, or by mail to the following address: Getinge AB, Att: Bolagsstämmoärenden, Box 8861, SE-402 72 Gothenburg, Sweden. To ensure inclusion in the notice and the agenda of the AGM, proposals must be received by the company no later than March 3, 2026.

Risk management

External risks

	Description	Potential consequences	Management
External shocks, such as geopolitical risks, natural disasters, terrorism, pandemics, etc.	Rapidly emerging situations, which could affect large geographical areas, a single country, a region or a specific facility.	The primary risk of such events is that employees could be injured. In addition, operations can be disrupted, which could have a negative impact on sales and earnings. Price increases for customers is another scenario.	Active business intelligence can identify some of these risks at an early stage, which enables the Group to adapt to the changed circumstances. The Group is working actively on continuity risks. This also includes scenarios based on external shocks as part of Getinge's proactive risk management. Getinge conducts operations in Russia in accordance with international sanctions and regulations via a small sales company. The activities in the country are currently limited to fulfilling existing customer commitments. However, the circumstances for conducting operations in the country have gradually deteriorated. Getinge does not conduct any manufacturing operations in either Russia or Ukraine and has no major suppliers in these countries. When Russia invaded Ukraine in 2022, the Group's sales in Russia and Ukraine represented less than 1% of the Group's total net sales and equity. Despite the limited direct impact that the invasion has had on Getinge's operations in Russia and Ukraine, the Russian invasion of Ukraine may nevertheless have a negative impact on the development of the Group's earnings and position. However, it is difficult at the current time to assess the future consequences of the conflict and its impact on the Group.
Interruptions in supply chains / dependence on external suppliers	Critical components manufactured by external suppliers are a vital part of Getinge's production chain. Serious production disruptions may arise if these components are not supplied on schedule.	As a consequence, vital equipment may not be delivered to customers, which may make it difficult or impossible to provide necessary healthcare.	Getinge is monitoring and actively adapting its operations based on escalating developments in spring 2025 regarding higher trade barriers, such as tariffs. The Group has a good overview of its supply chain and thus also the impact of tariffs and other trade barriers. Getinge has a geographically diversified purchasing and production strategy which partly can help to mitigate any negative consequences. Getinge can state that there is a risk of temporary business interruptions, for example, due to supply constraints for key components such as semiconductors, as a result of the uncertain global security situation. Getinge actively monitors critical suppliers, starting as early as when the partnership is established and continuing with routine evaluations. The Purchasing organization has tools for assessing risk and receives regular training in this area. The Group also works on ensuring that it has adequate levels of critical components in stock, in its own operations or with the relevant supplier. Interruptions of critical deliveries are managed as an important part of activities related to business continuity risks. See "Business interruptions."
Risks related to healthcare reimbursement systems	Political decisions can change the conditions for healthcare through changed reimbursement models for healthcare providers.	Changes to reimbursement systems could have significant effects on specific markets, with budget cuts or deferred funding potentially impacting the operations.	Although it is difficult to influence this risk directly, since decisions are outside the Group's control, it is mitigated by the presence in a large number of markets, which reduces the overall impact of individual changes.
New competitors and new technologies	Certain markets and product segments have niche players who offer solutions outside customary market behavior.	These competitors could capture market shares from established companies, including Getinge, which could result in lower sales and earnings.	Through continuous innovative development and market analysis, Getinge strives to be at the forefront, identify potential competitors and adapt to technological changes. The industry is also considered to have high barriers to entry since medical devices are subject to extensive regulatory requirements.
Increased expectations and new laws and regulations related to sustainability	The sustainability requirements and expectations placed on Getinge as a company are changing, and the scope is increasing rapidly.	Getinge's failure to meet the ever-more stringent environmental, social and governance requirements could have negative consequences on the company's reputation, operations and financial earnings. It may also impact the company's ability to recruit and retain competent staff, and risk disqualifying the company from participating in tenders with specific requirements.	By engaging with stakeholders and improving its materiality assessment and ERM process, Getinge increases its understanding of the expectations placed on the company. It is also beneficial that the company has adopted the focus areas that are to be prioritized moving forward. In addition, the company has developed its sustainability framework, focusing on the products and solutions placed on the market to ensure quality and corporate responsibility. This also leads to employee engagement. The company reports annually on its performance in sustainability in a transparent manner and is making preparations ahead of the forthcoming CSRD.
Increasing competition for public funds	Reduced public budgets for investing in medical devices impacts the total market potential.	Increased competition for limited public funds may lead to reduced funding for medical device investments, which in turn negatively impacts Getinge's sales figures.	Getinge works actively to offer solutions that improve the efficiency of healthcare, which is believed to generate healthy demand even where budgets are constrained.

Operational risks

	Description	Potential consequences	Management
Quality risks from a regulatory perspective	A large part of Getinge's product range is subject to strict legislation requiring extensive assessments, quality controls and detailed documentation.	It cannot be ruled out that Getinge's operations, financial position and earnings may be negatively impacted in the future if the company is unable to comply with regulatory requirements or if these requirements change.	To limit these risks, Getinge conducts extensive quality and regulatory activities. The Quality Compliance, Regulatory & Medical Affairs function has a representative in the Getinge Executive Team and also on the management teams of each business area, and in all R&D and production units. In addition, Getinge's sales force and service technicians receive quality and regulatory training every other year, and then have their certification renewed, which is a requirement for representing the company. Getinge conducts extensive research and development to ensure that the product portfolio meets all existing and future quality and regulatory requirements. The majority of the production facilities have ISO 13485 and/or ISO 9001 certification. In summary, Getinge invests significant resources in quality and regulatory matters, which is a top priority of the Group's strategy. As previously reported in the first quarter of 2023, the notifying body TÜV SÜD decided to temporarily suspend the CE certificate for Getinge's HLS and PLS sets for ECLS therapy and for Getinge's intra-aortic balloon pumps. As a result, the company initiated corrective actions to regain CE certification for these products. At the end of September 2024, TÜV SÜD reinstated Getinge's CE certificate for HLS and PLS sets, with certain conditions. The temporary suspension of Getinge's Cardiosave Intra-Aortic Balloon Pump, effective from March 2024, was extended until July 1, 2025. At the beginning of August 2025, TÜV SÜD reinstated Getinge's CE mark under certain conditions which Getinge has promised to fulfill. On May 8, 2024, the FDA sent a letter to healthcare providers in the US. The letter does not refer to any new field actions, but healthcare providers are encouraged to move from using Getinge's Cardiosave, Cardiohelp and HLS sets to alternative products and to continue to use Getinge's products only if no other options are available. As a result of the FDA's letter, Getinge has decided to suspend marketing activities for the relevant products in the US until outstanding actions related to quality improvements have been taken and approved. Sales of these products are restricted to customers who do not have any other alternatives. On November 15, 2024, the FDA published a Letter to Health Care Providers on its website, reminding them of the voluntary medical device removal and supply concerns related to all of Getinge's VasoView Hemopro Endoscopic Vessel Harvesting (EVH) Systems. Actions are being taken as agreed with the FDA.
Product quality from a customer perspective	In certain cases, Getinge's products do not meet customer expectations.	Product quality shortcomings could lead to customer seeking out alternative suppliers, which in turn could negatively impact sales and profitability over time.	Getinge applies a far-reaching quality process to ensure a high and even level of quality, which is an ongoing process that results in continuous improvements. When quality fails, it is important to rapidly rectify the fault during the first service visit. Getinge closely monitors the "first-time fix" factor of its services operations and works actively to make improvements.
Product liability risks	Healthcare suppliers run a risk, like other players in the healthcare industry, of being subject to product liability and other legal claims.	Such claims can involve large amounts and significant legal expenses. Getinge carries the customary indemnity and product liability insurances, but there is a risk that this insurance coverage may not fully cover product liability and other claims.	The most important way of managing these risks is the extensive quality-related and regulatory activities performed by the Group. Sources of potential future claims for damages are monitored through active incident reporting. Corrective and protective action (CAPA) is initiated when necessary to investigate the underlying cause, after which the product design may be corrected to remedy the fault. The settlement process regarding the Multidistrict Litigation (MDL) for surgical mesh implants, which Getinge announced previously, has been completed and payment of the majority of the settlement amount was made in the first quarter of 2023. The settlement is not an admission of liability or wrongdoing by the company. Getinge will continue to defend against any litigation that cannot be resolved under the final agreement. Costs for such processes are not expected to be material.
Information and data security	Leaks of confidential information or hacking into the Group's IT system resulting in restricted availability or interruptions of business-critical systems. In this context, extortion or sabotage cannot be excluded either.	Hacking into IT systems could lead to business interruptions. A loss of sensitive information may adversely affect confidence in the company. Leaks of personal data could lead to high fines.	Getinge has global IT services that ensure efficiency, coordination and security. Getinge's IT structure in production is largely decentralized, which reduces the consequences of certain cyber risks by spreading the risks across different systems. Getinge has centralized identity management and conducts extensive surveillance and monitoring of the central infrastructure to quickly detect and counteract security threats via its security operations center (SOC). Getinge regularly trains all employees to reduce cyber risks based on human factors.
Deficiencies in cybersecurity	Security deficiencies in the Group's digital offering, such as connected machines at customer sites and stricter legal requirements for processing personal data. In this context, extortion or sabotage cannot be excluded either.	Restricted availability of equipment delivered by Getinge to its customers, which could result in interruptions to the hospital operations and it not being possible to offer patients sufficient care in critical situations.	Getinge works diligently and systematically, following a risk-based approach, to ensure the integrity of its connected equipment. By continuously evaluating and prioritizing security risks, we can effectively protect both our systems and our customers' data. Comprehensive access testing is carried out before these solutions are offered to the Group's customers so as to identify and rectify potential vulnerabilities.
Business interruptions	Unforeseen events, such as natural disasters or fires, etc. can cause disruptions to production or the supply chain.	Such events may result in costly or delayed deliveries or non-delivery of products to Getinge's customers, which may adversely affect the Group's earnings.	Getinge takes continuous preventive action to ensure a high level of availability and delivery reliability, including regular inspections of the production facilities with the help of external expertise.
Non-compliance with laws and regulations mainly on business ethics	Breaches of laws and regulations related to, for example, competition, anti-corruption, AI, cyber security, data protection or trade restrictions.	Breaches of these regulations could lead to fines, sanctions and have a negative impact on the Getinge brand.	Getinge has previously provided information about ongoing investigations and agreements with the authorities regarding anti-competitive procedures in the sale of medical devices in Brazil. The process with the Brazilian federal authority, Comptroller General of the Union (CGU), is still ongoing. During the third quarter of 2024, Getinge made, in line with applicable accounting standards, a provision of SEK 482 M related to anticipated costs related to this process. The provision is the result of an ongoing constructive dialogue to reach a conclusion in the negotiations with the CGU. The final and definitive costs will be determined once the negotiations have been concluded, and such an amount could be lower or higher than the provision that has now been made. No information emerged in the period that would cause a change in the provision.

Dependence on meeting climate targets

Getinge is dependent on meeting the climate targets set to reach net zero emissions by 2050 that were approved by the SBTi. Getinge's analysis shows that the majority of emissions come from the purchases of goods, logistics and the use of sold products. As a result, the company does not have full control over its emissions and cannot therefore directly control their reduction.

If Getinge does not meet its climate targets, it could have a significant negative impact on the company's reputation and operations, in addition to negative climate impacts.

In addition to the investigations with CGU, Getinge has previously communicated that settlement agreements have been reached with the Brazilian Federal Prosecutor's Office (Ministério Público Federal) in 2018 and the competition authority, Administrative Council for Economic Defense (CADE) in 2019, both related to anti-competitive practices relating to the sale of medical devices. It cannot be ruled out that any further agreements with authorities may have a material impact on the company's financial earnings and position, but cannot currently be estimated neither in terms of amount nor timing. Getinge has a zero tolerance policy when it comes to contraventions of these regulations. The Group's Code of Conduct is very clear in this respect. The EVP Sustainability, Legal & Compliance represents the Ethics & Compliance function on the Getinge Executive Team, which highlights the high priority of these issues. A training program in business ethics is provided on an ongoing basis and the aim is for all employees to undergo such training at least once a year. The regulations also apply to external distributors who sell Getinge products.

Getinge is dependent on meeting the climate targets set to reach net zero emissions by 2050 that were approved by the SBTi. Getinge's analysis shows that the majority of emissions come from the purchases of goods, logistics and the use of sold products. As a result, the company does not have full control over its emissions and cannot therefore directly control their reduction.

Strategic risks

	Description	Potential consequences	Management
Lack of future skills	Risk of dependency on key people including lack of succession planning and ineffective processes to identify and spread critical know-how within the organization. Also the risk of being unable to attract and retain the right talent and skills.	A lack of future skills could lead to higher staff turnover, operational disruptions and damage the Getinge brand. In the future, it may have a negative impact on Getinge's long-term sustainability and growth, and ultimately affect Getinge's ability to attract and retain talent.	Getinge is continuously improving the succession planning process to ensure the global development of talent. Getinge is focusing on talent mobility and knowledge sharing and strives to create a culture and leadership that attracts both new and existing talent. Getinge's aim is to be a company where everyone can thrive and grow.
Digitization and innovation	Getinge's future growth depends on successful product development, particularly in digitalization. Innovation is crucial for maintaining and strengthening the company's leading position.	Innovation efforts are costly and it is not possible to guarantee that developed products will be commercially successful, which could result in impairment. In the long term, the Group's market position could be negatively affected if Getinge is unsuccessful in this area.	As a means of maximizing the return on investments in research and development, the Group applies a structured selection and planning process that includes careful analyses of the market, technological progress, choice of production method and selection of subcontractors. The actual development work is also conducted in a structured manner and each project undergoes a number of fixed controls. Getinge is particularly concerned with ensuring access to the right skills, retaining key individuals, being an attractive employer to recruit talent externally, and identifying and developing talent within the organization.
Fragmented product portfolio	Getinge's product portfolio consists, to a certain extent, of a large number of acquisitions that were made throughout the years within a variety of product categories.	An offering to our customers that, in certain parts, is too diverse could lead to Getinge lacking the critical mass needed to conduct fully efficient operations in all product categories.	Efforts are being made to enhance the efficiency of the customer offering under the framework of the ongoing strategic activities in each business area. The introduction of the new EU Medical Device Regulation means priorities need to be made regarding the certification of products under the new regulatory framework. Products have been selected that, over the long term, will be a part of the customer offering, which will lead to increased concentration as well as streamlining.
Risks related to intellectual property rights	Getinge's leading positions in many product segments are based on patent and trademark rights, which could lead to disputes with competitors.	Costly disputes over intellectual property rights could reduce the return on investment in research and development. It cannot be ruled out that the costs that could arise associated with this could be material.	Getinge closely monitors the activities of its competitors and actively defends its intellectual property rights through legal processes if necessary.
Financial risks	Getinge is exposed to a number of financial risks in its operations. Financial risks principally pertain to currency risks, interest-rate risks, and credit and counterparty risks.	Fluctuations in exchange rates and interest rates and changes in counterparties' credit profiles could adversely affect the Group's income statement and balance sheet.	Risk management is regulated by the finance policy adopted by the Board and a Treasury directive decided by the Getinge Executive Team based on the finance policy. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with the Getinge Executive Team and the treasury function. For more detailed information concerning these risks, refer to Note 18 of the Annual Report.
Profitability dependent on certain products and markets	Some products and markets contribute more to overall profitability.	If sales volumes in these markets were to decrease, it could have a negative impact on the Group's profitability.	Getinge works actively to monitor profitability per product and market in order to ensure profitability over time. To reduce the sensitivity of profitability, the Group actively works on ensuring that it has the right cost level in relation to the current price levels in the market. Getinge also works actively to establish itself in new markets.
Transferring the product portfolio	Long lead times in research and development due to comprehensive regulations and long validation processes are hampering rapid development to more sustainable product and packaging solutions. The medical device market is strictly regulated, partly to ensure patient safety, which can affect how quickly Getinge's products can become sustainable.	If it is not possible to transfer Getinge's product and packaging solutions to more sustainable solutions quickly enough, there is a risk that Getinge's reputation and competitiveness could decline.	Getinge will always prioritize patient safety and follow applicable regulations. Without impacting our fundamental approach, the company has expanded the implementation of eco-design principles into its development process and has begun to carry out life cycle assessments of its product and packaging solutions to ensure that advances can be made when the opportunity arises.

Assurance

The Board of Directors and CEO assure that the interim report provides a true and fair review of the Parent Company and the Group's operations, position and earnings and describes the material risks and uncertainties faced by the Parent Company and the Group.

Gothenburg, October 21, 2025

Johan Malmquist
Chairman,
AGM-elected Board member

Carl Bennet
Vice Chairman,
AGM-elected Board member

Johan Bygge
AGM-elected Board member

Cecilia Daun Wennborg
AGM-elected Board member

Ulrika Dellby
AGM-elected Board member

Dan Frohm
AGM-elected Board member

Mattias Perjos
President & CEO,
AGM-elected Board member

Malin Persson
AGM-elected Board member

Kristian Samuelsson
AGM-elected Board member

Fredrik Brattborn
Board member
Representative of the Swedish
Metalworkers' Union

Åke Larsson
Board member
Representative of the Swedish
Association of Graduate
Engineers

AUDITOR'S REPORT

Getinge AB (publ), reg. no. 556408-5032

Introduction

We have reviewed the condensed interim report for Getinge AB (publ) as at September 30, 2025 and for the nine months period then ended. The Board of Directors and the Managing Director are responsible for the preparation and presentation of this interim report in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

Scope of review

We conducted our review in accordance with the International Standard on Review Engagements, ISRE 2410 Review of Interim Financial Statements Performed by the Independent Auditor of the Entity. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and other generally accepted auditing standards in Sweden. The procedures performed in a review do not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material respects, in accordance with IAS 34 and the Swedish Annual Accounts Act regarding the Group, and in accordance with the Swedish Annual Accounts Act regarding the Parent Company.

Gothenburg, October 21, 2025

Ernst & Young AB

Fredrik Norrman
Authorized Public Accountant

Consolidated financial statements

Condensed consolidated income statement

SEK M	Note	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Net sales	2, 3	8,226	7,870	24,783	23,688	34,759
Cost of goods sold		-4,411	-4,315	-12,932	-12,589	-18,606
Gross profit	2, 3, 4	3,815	3,556	11,851	11,099	16,153
Selling expenses		-1,416	-1,401	-4,476	-4,362	-5,979
Administrative expenses		-1,090	-1,059	-3,405	-3,315	-4,654
Research and development costs		-307	-319	-968	-985	-1,431
Acquisition costs		-11	-29	-14	-45	-50
Restructuring costs		-23	-126	-345	-231	-848
Other operating income and expenses		-17	-438	-226	-392	-336
Operating profit (EBIT)	3, 4	952	184	2,418	1,769	2,854
Net financial items	3	-163	-152	-480	-398	-571
Profit after financial items	3	789	32	1,938	1,371	2,282
Taxes		-214	-24	-531	-385	-628
Net profit for the period		576	8	1,407	986	1,654
Attributable to:						
Parent Company shareholders		566	2	1,390	974	1,638
Non-controlling interests		10	7	17	12	16
Net profit for the period		576	8	1,407	986	1,654
Earnings per share, SEK ^{1) 2)}		2.08	0.01	5.10	3.58	6.01
Weighted average number of shares for calculation of earnings per share (000s)		272,370	272,370	272,370	272,370	272,370

1) Before and after dilution

2) Attributable to Parent Company shareholders

Consolidated statement of comprehensive income

SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Net profit for the period	576	8	1,407	986	1,654
Other comprehensive income					
Items that cannot be restated in profit for the period					
Actuarial gains/losses pertaining to defined-benefit pension plans	-4	-31	75	37	31
Tax attributable to items that cannot be restated in profit	1	6	-23	-9	-3
Items that can later be restated in profit for the period					
Translation differences	-190	-1,042	-3,508	249	2,063
Hedging of net investments	-35	-191	-651	63	393
Cash flow hedges	6	0	-8	-4	12
Tax attributable to items that can be restated in profit	6	39	136	-12	-83
Other comprehensive income for the period, net after tax	-216	-1,218	-3,980	324	2,412
Total comprehensive income for the period	360	-1,209	-2,573	1,310	4,066
Comprehensive income attributable to:					
Parent Company shareholders	351	-1,219	-2,578	1,291	4,038
Non-controlling interests	8	10	5	19	28
Total comprehensive income for the period	360	-1,209	-2,573	1,310	4,066

Condensed consolidated balance sheet

SEK M	Note	September 30 2025	September 30 2024	December 31 2024
Intangible assets		34,420	36,822	39,242
Tangible assets		3,526	3,740	3,902
Right-of-use assets		1,446	1,732	1,795
Financial assets		33	33	47
Deferred tax assets		800	953	770
Total non-current assets		40,225	43,280	45,757
Inventories		6,736	7,258	6,590
Accounts receivable		4,837	4,695	6,348
Other current receivables		2,142	2,141	2,263
Cash and cash equivalents	7	2,847	2,241	2,961
Total current assets		16,563	16,334	18,162
TOTAL ASSETS		56,789	59,614	63,918
Equity		29,375	30,467	33,210
Provisions for pensions, interest-bearing	7	2,479	2,657	2,700
Lease liabilities, long-term	7	1,017	1,283	1,309
Interest-bearing liabilities, long-term	7	8,545	5,916	6,971
Deferred tax liabilities		1,889	2,095	2,172
Other provisions, long-term		607	400	615
Other non-interest-bearing liabilities, long-term		519	1,581	1,892
Total long-term liabilities		15,056	13,932	15,660
Lease liabilities, current	7	439	453	491
Interest-bearing liabilities, current	7	1,428	3,216	1,956
Other provisions, current		1,644	1,574	1,714
Accounts payable		1,924	2,114	2,398
Other non-interest-bearing liabilities, current		6,923	7,859	8,488
Total current liabilities		12,358	15,215	15,047
TOTAL EQUITY AND LIABILITIES		56,789	59,614	63,918

Changes in equity for the Group

SEK M	Share capital	Other capital provided	Reserves ¹⁾	Retained earnings	Total	Non-controlling interests	Total equity
Opening balance at January 1, 2025	136	6,789	5,752	20,328	33,005	205	33,210
Total comprehensive income for the period	-	-	-4,019	1,442	-2,578	5	-2,573
Dividend	-	-	-	-1,253	-1,253	-10	-1,262
Closing balance at September 30, 2025	136	6,789	1,733	20,517	29,175	200	29,375
Opening balance at January 1, 2024	136	6,789	3,380	19,861	30,166	237	30,403
Total comprehensive income for the period	-	-	288	1,002	1,291	19	1,310
Dividend	-	-	-	-1,198	-1,198	-17	-1,215
Transactions with non-controlling interests	-	-	-	-	-	-31	-31
Closing balance at September 30, 2024	136	6,789	3,668	19,665	30,258	209	30,467
Opening balance at January 1, 2024	136	6,789	3,380	19,861	30,166	237	30,403
Total comprehensive income for the period	-	-	2,372	1,665	4,038	28	4,066
Dividend	-	-	-	-1,198	-1,198	-29	-1,228
Transactions with non-controlling interests	-	-	-	-	-	-31	-31
Closing balance at December 31, 2024	136	6,789	5,752	20,328	33,005	205	33,210

1) Reserves pertain to cash flow hedges, hedges of net investments and translation differences.

Condensed consolidated cash flow statement

SEK M	Note	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Operating activities						
Operating profit (EBIT)		952	184	2,418	1,769	2,854
Add-back of depreciation, amortization and write-downs	4	515	522	1,596	1,486	2,421
Other non-cash items ¹⁾		5	487	22	484	808
Add-back of restructuring costs ²⁾		23	126	326	231	523
Paid restructuring costs		-57	-95	-187	-168	-288
Financial items ³⁾		-127	-138	-390	-399	-542
Taxes paid		-171	-286	-457	-472	-742
Cash flow before changes in working capital		1,141	801	3,327	2,931	5,036
Changes in working capital						
Inventories		78	-197	-883	-769	46
Operating receivables		-132	168	834	849	-712
Operating liabilities ^{3) 4)}		-2	-90	-882	-472	208
Cash flow from operating activities		1,084	680	2,395	2,538	4,577
Investing activities						
Acquisition of operations	9	-	-2,788	-1,580	-3,087	-3,256
Investments in intangible assets and tangible assets		-297	-325	-944	-956	-1,309
Divestment of non-current assets		5	1	12	8	15
Cash flow from investing activities		-292	-3,111	-2,513	-4,035	-4,549
Financing activities						
Change in interest-bearing liabilities		317	2,457	1,495	2,579	2,207
Depreciation of lease liabilities		-123	-127	-375	-369	-506
Change in long-term receivables		3	32	3	29	31
Dividend paid		-3	-5	-1,263	-1,215	-1,227
Cash flow from financing activities		193	2,357	-140	1,024	504
Cash flow for the period		986	-73	-258	-472	532
Cash and cash equivalents at the beginning of the period		1,945	2,286	2,961	2,728	2,728
Translation differences		-83	27	144	-15	-299
Cash and cash equivalents at the end of the period		2,847	2,241	2,847	2,241	2,961

1) The provision for field actions for Cardiosave had an impact of SEK 297 M and negotiations with CGU in Brazil had an impact of SEK 482 M in 2024.

2) Excluding write-downs on non-current assets

3) Non-cash financial items were reclassified to operating liabilities for the 2024 comparative figures.

4) Whereof received and paid interests amounts to SEK -120 M (-127) and other financial items SEK -7 M (-11). Accumulated received and paid interests amounts to SEK -372 M (-379) and other financial items SEK -19 M (-20). For the full year 2024 received and paid interests amounted to SEK -517 M and other financial items SEK -25 M

Note 1 Accounting policies

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. For the Parent Company, the report has been prepared in accordance with the Swedish Annual Accounts Act and RFR 2. The accounting policies adopted are consistent with those applied for the 2024 Annual Report and should be read in conjunction with that Annual Report.

For practical reasons, the figures in this interim report have not been rounded off, which is why notes and tables may not total correct amounts. Unless otherwise specified, all figures pertain to SEK M and figures in parentheses pertain to the year-earlier period. The interim report provides alternative performance measures for monitoring the Group's operations.

Note 2 Net sales

	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Net sales, SEK M					
Capital goods	2,675	2,591	7,785	7,734	12,421
Recurring revenue					
Product sales	3,873	3,619	12,016	11,121	15,588
Service assignments incl. spare parts	1,678	1,660	4,983	4,833	6,750
Total recurring revenue	5,551	5,279	16,999	15,954	22,338
Total	8,226	7,870	24,783	23,688	34,759

	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Net sales, SEK M					
Revenue recognized at a point in time					
Acute Care Therapies	4,043	3,735	12,752	11,629	16,808
Life Science	831	810	2,434	2,445	3,579
Surgical Workflows	2,249	2,415	6,466	6,906	10,403
Total revenue recognized at a point in time	7,124	6,959	21,652	20,980	30,791
Revenue recognized over time					
Acute Care Therapies					
Service	273	272	777	727	1,045
Profit from ongoing projects	0	0	-	0	0
Other revenue recognized over time	23	15	66	66	96
Total Acute Care Therapies	296	287	843	794	1,140
Life Science					
Service	63	93	198	263	356
Profit from ongoing projects	203	98	539	321	580
Other revenue recognized over time	0	3	0	31	38
Total Life Science	266	194	737	615	973
Surgical Workflows					
Service	464	418	1,356	1,160	1,625
Profit from ongoing projects	37	2	98	50	96
Other revenue recognized over time	39	11	99	89	134
Total Surgical Workflows	540	430	1,552	1,299	1,855
Total revenue recognized over time	1,102	911	3,132	2,708	3,968
Total revenue recognized at a point in time and over time	8,226	7,870	24,783	23,688	34,759

For further information about the distribution of sales for each business area, see pages 6-8.

Note 3 Segment overview

	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Net sales, SEK M					
Acute Care Therapies	4,339	4,022	13,594	12,423	17,948
Life Science	1,097	1,003	3,171	3,060	4,552
Surgical Workflows	2,789	2,845	8,018	8,205	12,258
Total	8,226	7,870	24,783	23,688	34,759
Gross profit, SEK M					
Acute Care Therapies	2,339	2,078	7,586	6,825	9,615
Life Science	370	358	1,117	1,108	1,696
Surgical Workflows	1,107	1,120	3,148	3,166	4,842
Total	3,815	3,556	11,851	11,099	16,153
Operating profit (EBIT), SEK M					
Acute Care Therapies	690	208	2,157	1,718	2,065
Life Science	125	80	261	257	526
Surgical Workflows	238	14	337	102	703
Group functions and other (incl. eliminations) ¹⁾	-100	-118	-337	-308	-440
Operating profit (EBIT)	952	184	2,418	1,769	2,854
Net financial items	-163	-152	-480	-398	-571
Profit after financial items	789	32	1,938	1,371	2,282

1) Group functions and other refer mainly to central functions such as finance, communication, HR and other items, such as eliminations.

	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Net sales, SEK M					
EMEA	2,848	2,633	8,317	8,074	12,182
<i>of which, Sweden</i>	<i>116</i>	<i>166</i>	<i>439</i>	<i>434</i>	<i>617</i>
Americas	3,723	3,677	11,617	11,003	15,516
<i>of which, USA</i>	<i>3,371</i>	<i>3,293</i>	<i>10,500</i>	<i>9,865</i>	<i>13,929</i>
APAC	1,655	1,560	4,849	4,611	7,061
Total	8,226	7,870	24,783	23,688	34,759

Note 4 Depreciation, amortization and write-downs

SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Acquired intangible assets	-93	-82	-294	-198	-320
Intangible assets	-148	-160	-462	-460	-928
Right-of-use assets	-128	-132	-392	-390	-534
Tangible assets	-147	-148	-448	-437	-639
Total	-515	-522	-1,596	-1,486	-2,421
<i>Write-downs included in total</i>	<i>-4</i>	<i>1</i>	<i>-23</i>	<i>-</i>	<i>-357</i>

SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Cost of goods sold	-235	-243	-719	-706	-960
Selling expenses	-160	-158	-498	-421	-625
Administrative expenses	-100	-104	-305	-310	-414
Research and development costs	-21	-17	-55	-50	-99
Restructuring costs	0	-	-19	-	-325
Total	515	-522	-1,596	-1,486	-2,421
<i>Write-downs included in total</i>	<i>-4</i>	<i>1</i>	<i>-23</i>	<i>-</i>	<i>-357</i>

Note 5 Quarterly results

SEK M	Jul-Sep 2025	Apr-Jun 2025	Jan-Mar 2025	Oct-Dec 2024	Jul-Sep 2024	Apr-Jun 2024	Jan-Mar 2024	Oct-Dec 2023
Net sales	8,226	8,238	8,320	11,071	7,870	8,305	7,513	9,903
Cost of goods sold	-4,411	-4,296	-4,225	-6,018	-4,315	-4,394	-3,880	-5,617
Gross profit	3,815	3,941	4,095	5,053	3,556	3,911	3,632	4,286
Operating expenses	-2,863	-3,074	-3,497	-3,969	-3,372	-3,081	-2,877	-3,149
Operating profit (EBIT)	952	867	598	1,084	184	830	755	1,137
Net financial items	-163	-147	-170	-173	-152	-130	-117	-152
Profit after financial items	789	721	428	911	32	700	638	986
Taxes	-214	-194	-124	-243	-24	-187	-174	-267
Net profit for the period	576	527	304	668	8	513	464	719

Note 6 Adjustment items

Adjusted EBITA, SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Acute Care Therapies	763	637	2,624	2,247	3,554
Life Science	141	101	318	315	608
Surgical Workflows	263	251	453	420	1,090
Group functions and other (incl. eliminations)	-89	-86	-323	-256	-383
Total	1,079	903	3,071	2,726	4,869

Adjustments of EBITA, SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Specification of items affecting comparability that impact EBITA					
Restructuring costs, Acute Care Therapies	-16	-97	-282	-151	-715
Restructuring costs, Life Science	-3	-6	-16	-26	-35
Restructuring costs, Surgical Workflows	-4	-19	-48	-47	-91
Provision for investigations with CGU in Brazil, Acute Care Therapies ¹⁾	-	-289	-	-289	-289
Provision for investigations with CGU in Brazil, Surgical Workflows ¹⁾	-	-193	-	-193	-193
Provision for field actions for Cardiosave, Acute Care Therapies ²⁾	-	-	-	-	-297
Other, Acute Care Therapies	-	-	-	-	-18
Group functions and other (incl. eliminations)	-11	-32	-14	-52	-57
Total	-33	-637	-359	-759	-1,695

Items affecting comparability per segment					
Acute Care Therapies	-16	-387	-282	-440	-1,319
Life Science	-3	-6	-16	-26	-35
Surgical Workflows	-4	-212	-48	-240	-284
Group functions and other (incl. eliminations)	-11	-32	-14	-52	-57
Total	-33	-637	-359	-759	-1,695

- 1) Reported in Other operating income and operating expenses
2) Reported in Cost of goods sold

EBITA, SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Acute Care Therapies	748	250	2,342	1,806	2,235
Life Science	138	95	302	289	573
Surgical Workflows	260	39	405	180	806
Group functions and other (incl. eliminations)	-100	-118	-337	-308	-440
Total	1,045	266	2,712	1,968	3,174

Effect of adjustment of tax, SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Amortization and write-down of acquired intangible assets ¹⁾	93	82	294	198	320
Items affecting comparability	33	637	359	759	1,695
Adjustment items, total	127	719	653	957	2,016
Tax on adjustment items ²⁾	-35	-109	-180	-175	-459
Adjustment for tax items affecting comparability	-	-	-	-	-
Total	-35	-109	-180	-175	-459

- 1) Excluding write-downs classified as items affecting comparability
2) Tax effect on tax deductible adjustment items

Note 7 Consolidated net interest-bearing debt

SEK M	September 30 2025	September 30 2024	December 31 2024
Interest-bearing liabilities, current	1,428	3,216	1,956
Interest-bearing liabilities, long-term	8,545	5,916	6,971
Provisions for pensions, interest-bearing	2,479	2,657	2,700
Lease liabilities, current	439	453	491
Lease liabilities, long-term	1,017	1,283	1,309
Interest-bearing liabilities	13,908	13,525	13,428
Less cash and cash equivalents	-2,847	-2,241	-2,961
Net interest-bearing cash/debt	11,061	11,284	10,467

Note 8 Key figures for the Group

Financial and operative key figures	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Key figures based on Getinge's financial targets					
Adjusted earnings per share ¹⁾ , SEK	2.42	2.24	6.84	6.45	11.73
Growth in adjusted earnings per share ¹⁾ , %	7.9	-15.8	6.1	5.9	27.6
Other operative and financial key figures					
Organic growth in order intake, %	4.7	7.4	4.0	5.9	6.3
Organic growth in net sales, %	9.5	0.2	6.6	3.0	4.9
Gross margin, %	46.4	45.2	47.8	46.9	46.5
Selling expenses, % of net sales	17.2	17.8	18.1	18.4	17.2
Administrative expenses, % of net sales	13.2	13.4	13.7	14.0	13.4
Research and development costs, gross as a % of net sales	5.5	6.0	5.9	6.3	6.0
Operating margin, %	11.6	2.3	9.8	7.5	8.2
EBITDA, SEK M	1,468	706	4,014	3,255	5,275
Average number of shares, thousands	272,370	272,370	272,370	272,370	272,370
Number of shares at the end of the period, thousands	272,370	272,370	272,370	272,370	272,370
Interest-coverage ratio, multiple			11.6	11.4	12.3
Net debt/equity ratio, multiple			0.38	0.37	0.32
Net debt/Rolling 12m adjusted EBITDA, multiple			1.6	2.0	1.6
Capital employed, SEK M			41,417	39,379	40,952
Return on capital employed, %			11.6	9.6	11.1
Return on equity, %			6.8	5.4	5.2
Equity/assets ratio, %			51.7	51.1	52.0
Equity per share, SEK			107.85	111.86	121.93
Number of employees			11,794	11,848	11,791

1) Before and after dilution

Alternative performance measures

Alternative performance measures refer to financial measures used by the company's management and investors to evaluate the Group's earnings and financial position and that cannot be directly read or derived from the financial statements. These financial measures are intended to facilitate analysis of the Group's performance. Accordingly, the alternative performance measures should be considered a supplement to the financial statements prepared in accordance with IFRS. The financial measures recognized in this report may differ from similar measures used by other companies.

	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Calculation of organic net sales					
Net sales	8,226	7,870	24,783	23,688	34,759
<i>Add-back of:</i>					
Currency translation	596	286	1,193	387	423
Acquired operations	-203	-535	-734	-1,500	-1,794
Net sales, organic	8,619	7,621	25,242	22,575	33,387

	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Adjusted gross profit, SEK M					
Gross profit	3,815	3,556	11,851	11,099	16,153
<i>Add-back of:</i>					
Depreciation, amortization and write-downs of intangible assets and tangible assets	235	243	719	706	960
Other items affecting comparability	-	-	-	-	297
Adjustment for write-downs included in other items affecting comparability	-	-	-	-	-
Adjusted gross profit	4,051	3,799	12,570	11,805	17,409

	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Adjusted EBITDA, SEK M					
Operating profit (EBIT)	952	184	2,418	1,769	2,854
<i>Add-back of:</i>					
Depreciation, amortization and write-downs of intangible assets and tangible assets	422	440	1,302	1,288	1,823
Amortization and write-down of acquired intangible assets	93	82	294	198	320
Other items affecting comparability	-	482	-	482	797
Acquisition and restructuring costs	33	155	359	276	898
Adjustment for write-downs included in other items affecting comparability and restructuring costs	0	-	-19	-	-46
Adjusted EBITDA	1,501	1,343	4,353	4,014	6,646

	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Adjusted EBITA, SEK M					
Operating profit (EBIT)	952	184	2,418	1,769	2,854
<i>Add-back of:</i>					
Amortization and write-down of acquired intangible assets	93	82	294	198	320
Other items affecting comparability	-	482	-	482	797
Acquisition and restructuring costs	33	155	359	276	898
Adjusted EBITA	1,079	903	3,071	2,726	4,869

	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Adjusted EBIT, SEK M					
Operating profit (EBIT)	952	184	2,418	1,769	2,854
<i>Add-back of:</i>					
Other items affecting comparability	-	482	-	482	797
Acquisition and restructuring costs	33	155	359	276	898
Adjusted EBIT	986	821	2,776	2,528	4,549

	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Adjusted net profit for the period, SEK M					
Net profit for the period	576	8	1,407	986	1,654
<i>Add-back of:</i>					
Amortization and write-down of acquired intangible assets	93	82	294	198	320
Other items affecting comparability	-	482	-	482	797
Acquisition and restructuring costs	33	155	359	276	898
Tax items affecting comparability	-	-	-	-	-
Tax on add-back items	-35	-109	-180	-175	-459
Adjusted net profit for the period	668	618	1,880	1,768	3,211

The calculation of adjusted earnings per share, before and after dilution, attributable to Parent Company shareholders, is based on the following information:					
Earnings (numerator), SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Adjusted net profit for the period	668	618	1,880	1,768	3,211
Adjusted net profit for the period attributable to non-controlling interest	-10	-7	-17	-12	-16
Adjusted net profit for the period attributable to the Parent Company shareholders, which form the basis for calculation of adjusted earnings per share	658	611	1,863	1,756	3,195
Number of shares (denominator)	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Weighted average number of ordinary shares for calculation of adjusted earnings per share (thousands)	272,370	272,370	272,370	272,370	272,370
Adjusted earnings per share, SEK	2.42	2.24	6.84	6.45	11.73

Note 9 Acquisitions

No acquisitions took place during the third quarter that had a material impact on the Group's financial earnings and position. The acquisition analyses of Paragonix Technologies, Inc. and Getinge Aseptic Solutions LLC were completed during the quarter.

Contingent considerations

Getinge signed agreements on contingent considerations in connection with acquisitions of assets and subsidiaries. Liabilities for these additional purchase prices are measured at fair value through profit or loss at Level 3 of the fair value hierarchy. The additional purchase prices are contingent on securing government approval for the acquired product development projects and contingent on the earnings performance of the acquired businesses. Future cash flows are discounted if the planned payment date exceeds 12 months. Assessments of future cash flows related to the contingent consideration are regularly reviewed by company management and recognized at fair value. The discount effect is recognized in profit or loss under financial items on an ongoing basis.

Contingent considerations	September 30 2025	September 30 2024	December 31 2024
Opening balance	3,280	498	498
Business combinations	-	2,967	3,112
Dissolution of provision	-	-13	-13
Fair value adjustments recognized in profit or loss	5	-	11
Payments	-1,599	-359	-512
Discount effect	60	12	32
Translation differences	-401	-97	152
Closing balance	1,344	3,009	3,280

Parent Company financial statements

Condensed Parent Company's income statement

SEK M	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Net sales	75	68	257	224	293
Administrative expenses	-86	-93	-282	-243	-328
Operating loss	-11	-25	-25	-19	-35
Result from participations in Group companies ¹⁾	43	2	2,134	1,731	1,743
Interest income and other similar income ²⁾	8	15	45	25	37
Interest expenses and other similar expenses ²⁾	-54	-56	-167	-163	-218
Profit/loss after financial items	-14	-62	1,987	1,576	1,527
Appropriations	-	-	-	-	139
Taxes	2	4	-6	-5	-39
Net profit/loss for the period³⁾	-12	-59	1,981	1,570	1,627

1) Primarily refers to dividends from Group companies that take place on an ongoing basis throughout the year.

2) Interest income and other similar income and interest expenses and other similar expenses include exchange-rate gains and losses attributable to the translation of financial receivables and liabilities measured in foreign currencies

3) Comprehensive income for the period corresponds to net profit for the period

Condensed Parent Company's balance sheet

SEK M	September 30 2025	September 30 2024	December 31 2024
Assets			
Intangible assets	-	0	-
Tangible assets	1	2	2
Participations in Group companies	31,572	29,492	29,582
Deferred tax assets	104	102	99
Current receivables from Group companies	1,222	1,468	1,244
Current receivables	80	95	18
Cash and bank balances	2	1	0
Total assets	32,981	31,160	30,946
Equity and liabilities			
Equity	26,397	25,612	25,669
Long-term liabilities	5,793	4,094	3,595
Other provisions	25	14	16
Current liabilities to Group companies	8	2	7
Current liabilities	758	1,437	1,660
Total equity and liabilities	32,981	31,160	30,946

Definitions

Financial terms

Adjusted earnings per share: Adjusted net profit for the period attributable to Parent Company shareholders in relation to average number of shares.

Adjusted EBIT: Operating profit (EBIT) with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted EBITA: EBITA with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted EBITDA: EBITDA with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted gross profit: Gross profit with add-back of depreciation, amortization and write-downs and other items affecting comparability.

Adjusted net profit for the period: Net profit for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs, other items affecting comparability and tax effect of add-back of income-statement items.

Adjusted profit before tax: Profit before tax for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs and other items affecting comparability.

Capital employed: Average total assets with add-back of cash and cash equivalents, other provisions, accounts payable and other non-interest-bearing liabilities.

Capital goods: Durable products that are not consumed when used.

Currency transaction effect: Exchange of current year's volumes of foreign currency at this year's exchange rates, compared with the exchange rates in the preceding year.

Earnings per share: Net profit attributable to Parent Company shareholders in relation to average number of shares.

EBIT: Operating profit.

EBITA margin: EBITA in relation to net sales.

EBITA: Operating profit (EBIT) before add-back of amortization and write-down of acquired intangible assets.

EBITDA margin: EBITDA in relation to net sales.

EBITDA: Operating profit (EBIT) with add-back of amortization, depreciation and write-downs.

Equity per share: Equity in relation to the number of shares at the end of the period.

Equity/assets ratio: Equity in relation to total assets.

Free cash flow: Cash flow from operating activities and investing activities, excluding acquisitions and divestment of operations.

Gross margin: Gross profit in relation to net sales.

Interest-coverage ratio: Rolling 12 months' adjusted EBITDA in relation to rolling 12 months' net interest.

Items affecting comparability: Acquisition and restructuring costs and other items affecting comparability. Other items affecting comparability are significant revenue/expenses that impact comparability between accounting periods. These items include, but are not limited to, write-downs, disputes and major gains and losses attributable to divestments of assets or businesses.

Net debt/equity ratio: Net interest-bearing debt in relation to equity.

Operating liabilities: Accounts payable, other provisions and other non-interest-bearing liabilities (contract liabilities, non-interest-bearing provisions for pensions and similar obligations, accrued expenses and deferred income as well as other liabilities).

Operating margin: Operating profit (EBIT) in relation to net sales.

Operating receivables: Accounts receivable and other current receivables (contract assets, prepaid expenses and accrued income, and other receivables).

Organic change: A financial change adjusted for currency, acquisitions and divestments of operations.

Recurring revenue: Revenue from sales of products that are continuously consumed as well as service, spare parts and similar items.

Return on capital employed: Rolling 12 months' adjusted EBIT in relation to capital employed.

Return on equity: Rolling 12 months' profit after tax in relation to average equity.

Sustainability terms

Double materiality assessment: The process of identifying an organization's impacts on people and the environment and the sustainability-related financial risks and opportunities for the organization. The results are also used to determine whether

a sustainability topic is to be included in the company's sustainability report.

Employee engagement: The engagement score in Getinge's employee survey.

ESRS: European Sustainability Reporting Standards.

Online customer training: The number of training courses held for customers. The total number of times a customer has completed an e-learning course or participated in a training webinar.

REC (Renewable Energy Certificates): Used to certify that electricity was generated from renewable sources.

Scope 1 & 2: Carbon emissions from production (in ton CO₂ equivalents). Scope 1 includes emissions from oil and gas consumption. Emissions from Getinge's vehicle fleet are excluded in the interim report but the amounts for the full-year are presented in the Sustainability Report. Scope 2 includes emissions from electricity, heating and cooling. Emissions from leased premises are excluded in the interim report but the amounts for the full-year are presented in the Sustainability Report.

Scope 3: Includes other indirect emissions, both upstream and downstream in the value chain, arising from activities such as freight transport, purchased goods and services, as well as emissions from the use of products sold.

WRAR (Work Related Accident Rate): The number of work-related accidents divided by the number of hours worked, normalized by multiplying by 200,000 hours.

Medical terms

Cardiopulmonary: Pertaining or belonging to both heart and lung.

Cardiovascular: Pertaining or belonging to both heart and blood vessels.

DPTE®-BetaBags: Bag that ensures contamination-free transfer of components.

ECMO: Extracorporeal membrane oxygenation, meaning oxygenation outside the body through a membrane. Put simply, a modified cardiac and respiratory machine that exchanges oxygen and carbon dioxide, like an artificial lung.

Endoscope: Equipment for visual examination of the body's cavities, such as the stomach.

Endovascular: Vascular treatment using catheter technologies.

EVH Endoscopic Vessel Harvesting is a minimally invasive technique for removing blood vessels, for example during coronary artery bypass surgery.

Extracorporeal life support (ECLS):

Oxygenation of the patient's blood outside the body (extracorporeal) using advanced medical technology.

Grafts: Artificial vascular implants.

Hemodynamic monitoring: Monitoring the balance between blood pressure and blood flow.

Low temperature sterilization: A device used to sterilize surgical instruments which cannot be sterilized with high temperature steam. It is mainly used for instruments used in the minimal invasive and robotic surgery.

NAVA: Neurally Adjusted Ventilatory Assist (NAVA) identifies the electric activity that

activates the diaphragm and using these signals adapts the ventilation to the patient's respiratory rhythm.

Perfusionist: A healthcare professional who operates the heart-lung machine during surgery.

Stent: A tube for endovascular widening of blood vessels.

Sterilizer: A device to eliminate microorganisms on surgical instruments, usually by high temperature with steam.

Vascular intervention: A medical procedure conducted through vascular puncturing instead of using an open surgery method.

Ventilator: Medical device to help patients breath.

Vessel harvesting: The name of the process for removing blood vessels from the body.

WIS: Product category Washers Isolators Sterilizers.

Geographic areas

Americas: North, South and Central America.

APAC: Asia and Pacific (excluding Middle East).

EMEA: Europe, Middle East and Africa.

Teleconference

A teleconference with President & CEO Mattias Perjos and CFO Agneta Palmér will be held on October 21, 2025 at 10:00–11:00 a.m. CEST.

Fund managers, analysts and the media are invited to the teleconference.

Register via <https://events.inderes.com/getinge/q3-report-2025/dial-in> to participate in the teleconference. After registering, you will receive a telephone number and a conference ID to log in to the teleconference. You can ask questions verbally at the teleconference.

A presentation will be held during the telephone conference. To access the presentation, click on <https://getinge.events.inderes.com/q3-report-2025>. A recording will be available at <https://getinge.events.inderes.com/q3-report-2025> for three years.

Financial information

Updated information on, for example, the Getinge share and corporate governance is available on Getinge's website www.getinge.com. The Annual Report, year-end report and interim reports are published in Swedish and English and are available for download at www.getinge.com. The preliminary dates for financial communication are provided below:

January 27, 2026	Q4 Report 2025
April 21, 2026	Q1 Report 2026
April 21, 2026	Annual General Meeting

Contact

David Kördel, Head of Investor Relations
+46 (0)10 335 0077
david.kordel@getinge.com

This information is such that Getinge AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on October 21, 2025 at 8:00 a.m. CEST.

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs about 12,000 people worldwide and the products are sold in more than 135 countries.
Getinge has been listed on Nasdaq OMX Stockholm, Nordic Large Cap since 1993.

Getinge AB (publ) | Lindholmspiren 7A, 417 56 Gothenburg, Sweden | Tel: +46 (0)10 335 0000 | E-mail: info@getinge.com |
Corp. Reg. No.: 556408-5032 | www.getinge.com